Silo Pharma Statistics
Total Valuation
Silo Pharma has a market cap or net worth of $3.75 million. The enterprise value is -$3.43 million.
Important Dates
The next estimated earnings date is Friday, May 16, 2025, after market close.
| Earnings Date | May 16, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Silo Pharma has 4.48 million shares outstanding. The number of shares has increased by 19.50% in one year.
| Current Share Class | 4.48M |
| Shares Outstanding | 4.48M |
| Shares Change (YoY) | +19.50% |
| Shares Change (QoQ) | +4.38% |
| Owned by Insiders (%) | 4.30% |
| Owned by Institutions (%) | 7.31% |
| Float | 4.29M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 41.60 |
| Forward PS | n/a |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29
| Current Ratio | 4.29 |
| Quick Ratio | 4.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -925.59 |
Financial Efficiency
Return on equity (ROE) is -78.37% and return on invested capital (ROIC) is -52.47%.
| Return on Equity (ROE) | -78.37% |
| Return on Assets (ROA) | -38.81% |
| Return on Invested Capital (ROIC) | -52.47% |
| Return on Capital Employed (ROCE) | -81.76% |
| Revenue Per Employee | $24,034 |
| Profits Per Employee | -$1.46M |
| Employee Count | 3 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.35% in the last 52 weeks. The beta is 1.71, so Silo Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.71 |
| 52-Week Price Change | -52.35% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 35.30 |
| Average Volume (20 Days) | 175,925 |
Short Selling Information
The latest short interest is 67,438, so 1.50% of the outstanding shares have been sold short.
| Short Interest | 67,438 |
| Short Previous Month | 134,766 |
| Short % of Shares Out | 1.50% |
| Short % of Float | 1.57% |
| Short Ratio (days to cover) | 1.41 |
Income Statement
In the last 12 months, Silo Pharma had revenue of $72,102 and -$4.39 million in losses. Loss per share was -$1.19.
| Revenue | 72,102 |
| Gross Profit | 66,264 |
| Operating Income | -4.71M |
| Pretax Income | -3.60M |
| Net Income | -4.39M |
| EBITDA | -4.70M |
| EBIT | -4.71M |
| Loss Per Share | -$1.19 |
Full Income StatementBalance Sheet
The company has $7.08 million in cash and n/a in debt, giving a net cash position of $7.08 million or $1.58 per share.
| Cash & Cash Equivalents | 7.08M |
| Total Debt | n/a |
| Net Cash | 7.08M |
| Net Cash Per Share | $1.58 |
| Equity (Book Value) | 5.03M |
| Book Value Per Share | 1.12 |
| Working Capital | 5.46M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.83M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Full Cash Flow StatementMargins
| Gross Margin | 91.90% |
| Operating Margin | -6,526.44% |
| Pretax Margin | -6,092.59% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |